10x Genomics, Inc. Increase (Decrease) in Deferred Liabilities
10x Genomics, Inc. (TXG) reported Increase (Decrease) in Deferred Liabilities of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2022-02-18
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2020-12-31 was $0.00.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-12-31 was -$111.00K, a 103.88% decline year-over-year.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for the quarter ending 2019-09-30 was $1.15M.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for fiscal 2021 was $0.00.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for fiscal 2019 was $12.73M, a 282.51% increase from fiscal 2018.
- 10x Genomics, Inc. increase (decrease) in deferred liabilities for fiscal 2018 was $3.33M.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-18 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $1.04M derived: sum of 2 quarters · filed 2022-02-18 | $5.45M derived: sum of 3 quarters · filed 2022-02-18 | $12.73M 10-K · filed 2022-02-18 |
| 2019-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $5.56M derived: sum of 2 quarters · filed 2020-11-12 | $12.84M 10-Q · filed 2020-11-12 | $15.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $11.69M 10-Q · filed 2020-08-12 | $14.55M derived: sum of 3 quarters · filed 2021-02-26 | |
| 2019-03-31 | $7.28M 10-Q · filed 2020-05-12 | $10.14M derived: sum of 2 quarters · filed 2021-02-26 | ||
| 2018-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $3.33M 10-K · filed 2021-02-26 | ||
| 2018-09-30 | $470.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | -$68.00K 10-K · filed 2020-02-27 |